Kim, Edward

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 1,092

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)

Halmos, B., Tan, E.-H., Soo, R. A., Cadranel, J., Lee, M. K., Foucher, P., Hsia, T.-C., Hochmair, M., Griesinger, F., Hida, T., et al. (2019) · Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 74

Abstract 2308: Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC)

Hong, D. S., Kuboki, Y., Yaeger, R., Strickler, J. H., Masuishi, T., Langer, C., Shergill, A., Kim, E., Hindoyan, A., Tran, Q., et al. (2023) · Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 8